Literature DB >> 8690105

The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism.

I I Müderris1, F Bayram, Y Sahin, F Keleştimur, A Tutuş, D Ayata.   

Abstract

OBJECTIVE: To investigate the effects of low dose flutamide (250 mg/d) on hirsutism score and hormone levels in women with hirsutism.
DESIGN: Nonrandomized, prospective clinical trial. PATIENTS: Forty-one patients with moderate-severe hirsutism were included in the study. INTERVENTION: Hirsute patients received 250 mg/d flutamide for a period of 6 months. MAIN OUTCOME MEASURES: Hirsutism score, FSH, LH, E2, total T, free T, androstenedione, DHEAS, PRL, 17-hydroxyprogesterone, and sex hormone-binding globulin levels were detected in all the patients before treatment and every 3 months during treatment.
RESULTS: Treatment with the antiandrogen flutamide resulted in a particularly rapid and marked decrease in the hirsutism score, which decreased from 17.48 +/- 5.35 to 5.07 +/- 2.89 after 6 months. No significant changes in the levels of hormone and no serious side effects were observed in the study.
CONCLUSION: The low-dose flutamide, 250 mg/d, is a cost-effective drug in the treatment of hirsutism. Low-dose flutamide may be used in place of high-dose flutamide, 500 to 750 mg/d.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690105     DOI: 10.1016/s0015-0282(16)58442-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism.

Authors:  I I Müderris; F Bayram
Journal:  J Endocrinol Invest       Date:  1999-03       Impact factor: 4.256

Review 2.  A risk-benefit assessment of pharmacological therapies for hirsutism.

Authors:  E Carmina
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism.

Authors:  Y Sahin; F Bayram; F Keleştimur; I Müderris
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.